These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17299191)

  • 1. Cyclooxygenase inhibitors and cardiovascular risk.
    Andersohn F; Suissa S; Garbe E
    JAMA; 2007 Feb; 297(6):586-7; author reply 587-8. PubMed ID: 17299191
    [No Abstract]   [Full Text] [Related]  

  • 2. Celecoxib pathways: pharmacokinetics and pharmacodynamics.
    Gong L; Thorn CF; Bertagnolli MM; Grosser T; Altman RB; Klein TE
    Pharmacogenet Genomics; 2012 Apr; 22(4):310-8. PubMed ID: 22336956
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas".
    Cen YY
    Circulation; 2007 Mar; 115(12):e348; author reply e349. PubMed ID: 17389275
    [No Abstract]   [Full Text] [Related]  

  • 4. Celecoxib.
    Cheung R; Lowry S
    J R Soc Med; 2006 Jul; 99(7):336. PubMed ID: 16816261
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiovascular events: a class effect by COX-2 inhibitors].
    Araujo LF; Soeiro Ade M; Fernandes Jde L; Serrano Júnior CV
    Arq Bras Cardiol; 2005 Sep; 85(3):222-9. PubMed ID: 16200274
    [No Abstract]   [Full Text] [Related]  

  • 6. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 9. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
    Cimbollek S; Quiralte J; Avila R
    N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A; Seripa D; Franceschi M; Scarcelli C; Colaizzo D; Grandone E; Niro V; Andriulli A; Leandro G; Di Mario F; Dallapiccola B
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are COX-2 inhibitors safe for anyone.
    Bloomfeld RS
    Inflamm Bowel Dis; 2006 Sep; 12(9):922-3. PubMed ID: 16954813
    [No Abstract]   [Full Text] [Related]  

  • 12. Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
    Harv Health Lett; 2005 Mar; 30(5):1-3. PubMed ID: 16526110
    [No Abstract]   [Full Text] [Related]  

  • 13. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
    Malhi H; Atac B; Daly AK; Gupta S
    Postgrad Med J; 2004 Feb; 80(940):107-9. PubMed ID: 14970301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases].
    Guo ZR
    Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.
    Stempak D; Bukaveckas BL; Linder M; Koren G; Baruchel S
    Clin Pharmacol Ther; 2005 Sep; 78(3):309-10. PubMed ID: 16153401
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefit versus risk in the use of non-selective NSAIDs and selective COX-2 inhibitors.
    Aalbers J
    Cardiovasc J Afr; 2012 Jul; 23(6):356. PubMed ID: 23091830
    [No Abstract]   [Full Text] [Related]  

  • 17. Risks and benefits of celecoxib to prevent colorectal adenomas.
    Andersohn F; Suissa S; Garbe E
    N Engl J Med; 2006 Nov; 355(22):2371; author reply 2371-3. PubMed ID: 17135594
    [No Abstract]   [Full Text] [Related]  

  • 18. Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test.
    Arakawa Y; Nakai N; Katoh N
    J Dermatol; 2011 Dec; 38(12):1185-8. PubMed ID: 22103805
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Questions #6. Does celecoxib increase cardiovascular risk?
    Mayer BJ; Lamfers R; Feldstein DA
    WMJ; 2005 Nov; 104(8):15-6. PubMed ID: 16425910
    [No Abstract]   [Full Text] [Related]  

  • 20. Arthritis medicines and cardiovascular events--"house of coxibs".
    Topol EJ
    JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.